The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Abstract
Objective.: To determine the attributable (direct) mortality and morbidity caused by carbapenem-resistant Klebsiella pneumoniae bacteremia. Design.: A matched retrospective, historical cohort design, using a stepwise procedure to stringendy match the best control subjects to the best case subjects. Setting.: A 1,000-bed tertiary-care university teaching hospital. Patients.: Case subjects were defined as adult patients with carbapenem-resistant K. pneumoniae bacteremia during the period from October 2005 through October 2008. Control subjects were defined as patients who were very similar to case subjects except that they did not have bacteremia. Methods.: Matching potential control subjects to case subjects was performed at a 1:1 ratio using a computerized record system. The criteria used included same hospitalization period, similar Charlson comorbidity index, same underlying disease, same age within 10 years, and same sex. Demographic and clinical characteristics were collected from medical records. Results.: During the study period, 319 patients developed an infection due to carbapenem-resistant K. pneumoniae. Of these 319 patients, 39 (12.2%) developed a bloodstream infection, for an overall rate of 0.59 episodes of carbapenem-resistant K. pneumoniae bacteremia per 10,000 patient-days. We excluded 7 patients from our study, leaving a total of 32 case subjects in our cohort. Case subjects were significandy more likely than control subjects (n = 32) to require care in an intensive care unit (12 case subjects [37.5%] vs 3 control subjects [9.4%]), ventilator support (17 case subjects [53.1%] vs 8 control subjects [25%]), and use of a central venous catheter (19 case subjects [59.4%] vs 9 control subjects [28.1%]). For case subjects, the crude mortality rate was 71.9% (ie, 23 of the 32 case subjects died); for control subjects, the crude mortality rate was 21.9% (ie, 7 of the 32 control subjects died) (P < .001. For case subjects, the attributable mortality was 50% (95% confidence interval [CI], 15.3%-98.6%). A mortality risk ratio of 3.3 (95% CI, 2.9-28.5) was found for case subjects with carbapenem-resistant K. pneumoniae bacteremia. Conclusions.: Patients with carbapenem-resistant K. pneumoniae require more intensive and invasive care. We have shown that the crude and attributable mortality rates associated with carbapenem-resistant K. pneumoniae bacteremia were striking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic Susceptibility Testing by a Standardized Single Disk Method
Bauer, A. W., Kirby, W. M. M., Sherris, J. C., & Turck, M. (1966) · American Journal of Clinical Pathology · doi:10.1093/ajcp/45.4_ts.493 · Cited by 18,523
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
Rangel-Frausto, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.117 · Cited by 2,104
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Pittet, D. (1994) · JAMA · doi:10.1001/jama.1994.03510440058033 · Cited by 926
Patel, G., Huprikar, S., Factor, S. H., Jenkins, S. G., & Calfee, D. P. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/592412 · Cited by 836
Schwaber, M. J., Klarfeld-Lidji, S., Navon-Venezia, S., Schwartz, D., Leavitt, A., & Carmeli, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-07 · Cited by 483
Evaluation of Methods To Identify the Klebsiella pneumoniae Carbapenemase in Enterobacteriaceae
Anderson, K. F., Lonsway, D. R., Rasheed, J. K., Biddle, J., Jensen, B., McDougal, L. K., Carey, R. B., Thompson, A., Stocker, S., Limbago, B., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00015-07 · Cited by 355
Coagulase-Negative Staphylococcal Bacteremia: Mortality and Hospital Stay
Martin, M. A., Pfaller, M. A., & Wenzel, R. P. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-1-9 · Cited by 333
Vancomycin-Resistant Enterococcal Bacteremia: Natural History and Attributable Mortality
Edmond, M. B., Ober, J. F., Dawson, J. D., Weinbaum, D. L., & Wenzel, R. P. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.6.1234 · Cited by 301
Cited by
Global Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Hypervirulent Klebsiella pneumoniae
Russo, T. A., & Marr, C. M. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-19 · Cited by 1,311
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Antimicrobial resistance: A global emerging threat to public health systems
Ferri, M., Ranucci, E., Romagnoli, P., & Giaccone, V. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1077192 · Cited by 1,049
Carbapenem resistance in Enterobacteriaceae: here is the storm!
Nordmann, P., Dortet, L., & Poirel, L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.03.003 · Cited by 1,038
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Li, B., & Webster, T. J. (2018) · Journal of Orthopaedic Research · doi:10.1002/jor.23656 · Cited by 907
The negative impact of antibiotic resistance
Friedman, N. D., Temkin, E., & Carmeli, Y. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.002 · Cited by 870
Carbapenem Resistance: A Review
Codjoe, F., & Donkor, E. (2017) · Medical Sciences · doi:10.3390/medsci6010001 · Cited by 746
Xu, L., Sun, X., & Ma, X. (2017) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-017-0191-3 · Cited by 661
Schwaber, M. J., Lev, B., Israeli, A., Solter, E., Smollan, G., Rubinovitch, B., Shalit, I., Carmeli, Y., & the Israel Carbapenem-Resistant Enterobacteriaceae Working Group (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir025 · Cited by 453
Tamma, P. D., Goodman, K. E., Harris, A. D., Tekle, T., Roberts, A., Taiwo, A., & Simner, P. J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw741 · Cited by 402
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
Jean, S.-S., Harnod, D., & Hsueh, P.-R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.823684 · Cited by 366
Hu, F.-P., Guo, Y., Zhu, D.-M., Wang, F., Jiang, X.-F., Xu, Y.-C., Zhang, X.-J., Zhang, C.-X., Ji, P., Xie, Y., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.001 · Cited by 361
Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections
Ben-David, D., Kordevani, R., Keller, N., Tal, I., Marzel, A., Gal-Mor, O., Maor, Y., & Rahav, G. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03478.x · Cited by 353
Lomovskaya, O., Sun, D., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Griffith, D. C., & Dudley, M. N. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-17 · Cited by 353
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes
van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.11.009 · Cited by 352
Cannatelli, A., D'Andrea, M. M., Giani, T., Di Pilato, V., Arena, F., Ambretti, S., Gaibani, P., & Rossolini, G. M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01480-13 · Cited by 351
Capone, A., Giannella, M., Fortini, D., Giordano, A., Meledandri, M., Ballardini, M., Venditti, M., Bordi, E., Capozzi, D., Balice, M. P., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12070 · Cited by 346
DeLeo, F. R., Chen, L., Porcella, S. F., Martens, C. A., Kobayashi, S. D., Porter, A. R., Chavda, K. D., Jacobs, M. R., Mathema, B., Olsen, R. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321364111 · Cited by 329
Emergence of Klebsiella pneumoniae Carbapenemase-Producing Bacteria
Arnold, R. S., Thom, K. A., Sharma, S., Phillips, M., Kristie Johnson, J., & Morgan, D. J. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e3181fd7d5a · Cited by 307
Magiorakos, A. P., Burns, K., Rodríguez Baño, J., Borg, M., Daikos, G., Dumpis, U., Lucet, J. C., Moro, M. L., Tacconelli, E., Simonsen, G. S., et al. (2017) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-017-0259-z · Cited by 297
Grundmann, H., Livermore, D. M., Giske, C. G., Cantón, R., Rossolini, G. M., Campos, J., Vatopoulos, A., Gniadkowski, M., Toth, A., Pfeifer, Y., et al. (2010) · Eurosurveillance · doi:10.2807/ese.15.46.19711-en · Cited by 284
Holden, V. I., Wright, M. S., Houle, S., Collingwood, A., Dozois, C. M., Adams, M. D., & Bachman, M. A. (2018) · mSphere · doi:10.1128/msphere.00125-18 · Cited by 42
Metadata
- Authors
- Borer, A., Saidel-Odes, L., Riesenberg, K., Eskira, S., Peled, N., Nativ, R., Schlaeffer, F., & Sherf, M.
- Venue
- Infection Control & Hospital Epidemiology
- Publisher
- Cambridge University Press (CUP)
- Published
- 2009-10
- Volume
- 30
- Issue
- 10
- Pages
- 972-976
- ISSN
- 0899-823X (ISSN-L)
- 1559-6834
- OpenAlex
- W2089720823
- Cited by
- 389
- References
- 17
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.